[go: up one dir, main page]

PE20091265A1 - Nanoparticulas que contienen pioglitazona - Google Patents

Nanoparticulas que contienen pioglitazona

Info

Publication number
PE20091265A1
PE20091265A1 PE2008002062A PE2008002062A PE20091265A1 PE 20091265 A1 PE20091265 A1 PE 20091265A1 PE 2008002062 A PE2008002062 A PE 2008002062A PE 2008002062 A PE2008002062 A PE 2008002062A PE 20091265 A1 PE20091265 A1 PE 20091265A1
Authority
PE
Peru
Prior art keywords
pioglitazone
nanoparticles containing
containing pioglitazone
preparations
nanoparticle
Prior art date
Application number
PE2008002062A
Other languages
English (en)
Inventor
Kensuke Egashira
Original Assignee
Univ Kyushu Nat Univ Corp
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40440298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091265(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kyushu Nat Univ Corp, Takeda Pharmaceutical filed Critical Univ Kyushu Nat Univ Corp
Publication of PE20091265A1 publication Critical patent/PE20091265A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/422—Anti-atherosclerotic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

REFERIDA A UNA NANOPARTICULA QUE COMPRENDE PIOGLITAZONA O UNA SAL DEL MISMO Y UN POLIMERO BIOCOMPATIBLE TAL COMO UN COPOLIMERO ACIDO LACTICO-ACIDO GLICOLICO, DONDE LA PIOGLITAZONA SE ENCUENTRA EN UNA CANTIDAD DE ENTRE 0,1% A 10% EN PESO. TAMBIEN ESTA REFERIDA A UN STENT Y PREPARACIONES FARMACEUTICAS QUE COMPRENDEN DICHA PARTICULA. DICHAS PREPARACIONES SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES ARTERIOESCLEROTICAS
PE2008002062A 2007-12-13 2008-12-12 Nanoparticulas que contienen pioglitazona PE20091265A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007322409 2007-12-13
JP2008125071 2008-05-12

Publications (1)

Publication Number Publication Date
PE20091265A1 true PE20091265A1 (es) 2009-09-18

Family

ID=40440298

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002062A PE20091265A1 (es) 2007-12-13 2008-12-12 Nanoparticulas que contienen pioglitazona

Country Status (10)

Country Link
US (1) US8337896B2 (es)
EP (1) EP2219625B1 (es)
JP (1) JP5382879B2 (es)
CN (1) CN101969934B (es)
AR (1) AR069674A1 (es)
CL (1) CL2008003699A1 (es)
ES (1) ES2392375T3 (es)
PE (1) PE20091265A1 (es)
TW (1) TW200932223A (es)
WO (1) WO2009075391A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371370A1 (en) 2010-04-01 2011-10-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization
CN103068404B (zh) * 2010-06-11 2015-11-25 独立行政法人科学技术振兴机构 药物多聚物微粒及其制造方法
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
WO2012068476A2 (en) 2010-11-18 2012-05-24 University Of South Florida Poly(vinyl benzoate) nanoparticles for molecular delivery
JP2012125180A (ja) * 2010-12-15 2012-07-05 Kowa Co 下肢虚血モデル動物
US8734898B2 (en) 2012-09-21 2014-05-27 E I Du Pont De Nemours And Company Method for producing encapsulated nanoparticles
CN103006567A (zh) * 2012-12-21 2013-04-03 中国海洋大学 一种包载亲水性药物的壳聚糖-聚乳酸羟基乙酸复合纳米微粒的制备方法
US10232090B2 (en) * 2013-08-23 2019-03-19 Southwest Research Institute Electrophoretically deposited strontium fluoride nanoparticle/polymer coatings for medical implants
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
CN109481419B (zh) * 2019-01-16 2021-04-02 中国人民解放军陆军军医大学第一附属医院 一种罗格列酮纳米制剂及其制备方法和用途
CO2020001235A1 (es) * 2020-02-03 2021-08-09 Univ Pontificia Bolivariana Stent
US20230355542A1 (en) * 2022-05-04 2023-11-09 Yasin Oduk Drug-eluting device with genetic and chemical therapeutics for treating or preventing vascular access dysfunctions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75469A (en) * 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
ES2259459T3 (es) 1997-11-19 2006-10-01 Takeda Pharmaceutical Company Limited Nuevos inhibidores de apoptosis.
CA2349865C (en) * 1999-06-21 2014-08-19 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
CN1507357A (zh) * 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
DE60237594D1 (de) 2001-04-25 2010-10-21 Takeda Pharmaceutical Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
WO2003013609A1 (fr) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
JP2003113120A (ja) * 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
FR2830017B1 (fr) * 2001-09-27 2005-11-04 Centre Nat Rech Scient Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
JP4707937B2 (ja) * 2003-02-28 2011-06-22 ホソカワミクロン株式会社 薬物含有複合粒子の製造方法および経肺製剤
JP2004267283A (ja) * 2003-03-05 2004-09-30 Terumo Corp 体内埋込医療材料および体内埋込医療器具
US8119153B2 (en) * 2004-08-26 2012-02-21 Boston Scientific Scimed, Inc. Stents with drug eluting coatings
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
JP2007119396A (ja) 2005-10-28 2007-05-17 Hosokawa Funtai Gijutsu Kenkyusho:Kk 核酸化合物封入ナノ粒子を含む経肺投与用医薬製剤
US20070098802A1 (en) * 2005-10-31 2007-05-03 Isaac Farr Organic nanoparticles and associated methods
JP4297221B2 (ja) 2006-02-15 2009-07-15 株式会社ホソカワ粉体技術研究所 薬剤溶出型ステントの製造方法
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
US20080026040A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分

Also Published As

Publication number Publication date
AR069674A1 (es) 2010-02-10
EP2219625A1 (en) 2010-08-25
CN101969934A (zh) 2011-02-09
US20100331373A1 (en) 2010-12-30
US8337896B2 (en) 2012-12-25
JP2011506268A (ja) 2011-03-03
WO2009075391A1 (en) 2009-06-18
CN101969934B (zh) 2012-11-21
EP2219625B1 (en) 2012-08-01
ES2392375T3 (es) 2012-12-10
CL2008003699A1 (es) 2009-10-09
TW200932223A (en) 2009-08-01
JP5382879B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
PE20091265A1 (es) Nanoparticulas que contienen pioglitazona
Butler et al. Review of antimicrobial nanocoatings in medicine and dentistry: mechanisms of action, biocompatibility performance, safety, and benefits compared to antibiotics
Shcherbakov et al. CeO2 nanoparticle-containing polymers for biomedical applications: A review
Sharma et al. An insight into functionalized calcium based inorganic nanomaterials in biomedicine: Trends and transitions
Xue et al. Alkaline “nanoswords” coordinate ferroptosis-like bacterial death for antibiosis and osseointegration
Ning et al. Concentration ranges of antibacterial cations for showing the highest antibacterial efficacy but the least cytotoxicity against mammalian cells: implications for a new antibacterial mechanism
Harun-Ur-Rashid et al. Recent advances of silver nanoparticle-based polymer nanocomposites for biomedical applications
MX2013012458A (es) Suministro intravascular de composiciones de nanoparticulas y sus usos.
ES2721898T3 (es) Formulaciones estables para liofilizar partículas terapéuticas
Chen et al. “Photo-thermo-electric” dental implant for anti-infection and enhanced osteoimmunomodulation
NZ708506A (en) Methods of treating bladder cancer
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
PH12015501782A1 (en) Method for production of commercial nanoparticles and microparticle powders
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX2009012279A (es) Distribucion de micro y nanoparticulas con plaquetas.
EA201170039A1 (ru) Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
MX359793B (es) Producción de nanopartículas encapsuladas a escala comercial.
PE20110407A1 (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
BRPI0518101A (pt) métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
MX2019007448A (es) Composiciones de resina recicladas y dispositivos medicos desechables hechos de las mismas.
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior

Legal Events

Date Code Title Description
FA Abandonment or withdrawal